Go Back to Match Results for "trials"
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: urothelial carcinoma | brain metastasis | squamous cell carcinoma of the head and neck | non small cell lung cancer | solid tumor
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
Inclusion Criteria
Must have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic
Have adequate organ function
Have a performance status (PS) of less than or equal to on the Eastern Cooperative Oncology Group (ECOG) scale
Have discontinued previous treatments for cancer
Are able to swallow capsules
Exclusion Criteria
Currently enrolled in a clinical study
Have a serious concomitant systemic disorder
Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C
Have a significant cardiac condition
Have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required
